The early studies out of Israel showed the benefits of a hybrid response. It also makes sense when you consider that infection theoretically results in a response to the entire virus, or at least to those sites that are exposed, while the response to the vaccine is focused on the spike protein. Wouldn’t you think that a multi-valent mRNA…
The early studies out of Israel showed the benefits of a hybrid response. It also makes sense when you consider that infection theoretically results in a response to the entire virus, or at least to those sites that are exposed, while the response to the vaccine is focused on the spike protein. Wouldn’t you think that a multi-valent mRNA vaccine that incorporated elements of the nucleocapsid protein, along with spike, wouid be advantageous?
Going for the spike was the easy target with the highest probability of success, which was achieved. If you can find it, I've commented before that we'll eventually have to address other sites than spike and RBD for eventual success. There are new vaccines based on other technologies than mRNA which look for the capsid protein.
One other thought: Early studies out of Israel had results that were often seen as too solid to be true, and we were already gun-shy following the hydroxychloroquin scandal in France. Further, Israel had only one vaccine (Pfizer) while we were looking at a broader choice. Finally, we've seen differences in different countries with regard to effectiveness against different VOCs.
The early studies out of Israel showed the benefits of a hybrid response. It also makes sense when you consider that infection theoretically results in a response to the entire virus, or at least to those sites that are exposed, while the response to the vaccine is focused on the spike protein. Wouldn’t you think that a multi-valent mRNA vaccine that incorporated elements of the nucleocapsid protein, along with spike, wouid be advantageous?
Going for the spike was the easy target with the highest probability of success, which was achieved. If you can find it, I've commented before that we'll eventually have to address other sites than spike and RBD for eventual success. There are new vaccines based on other technologies than mRNA which look for the capsid protein.
One other thought: Early studies out of Israel had results that were often seen as too solid to be true, and we were already gun-shy following the hydroxychloroquin scandal in France. Further, Israel had only one vaccine (Pfizer) while we were looking at a broader choice. Finally, we've seen differences in different countries with regard to effectiveness against different VOCs.